The Core Answer: Same Molecule, Different Doses and Indications
Ozempic and Wegovy both contain semaglutide — they are chemically identical. The differences are in the approved maximum dose, the FDA-approved indication, the titration schedule, and consequently the typical insurance coverage. Understanding these differences matters because they affect what you can be prescribed, what your insurance will pay for, and what results you can expect.
FDA-Approved Indications
Ozempic is approved for Type 2 diabetes management and for reducing cardiovascular risk in adults with Type 2 diabetes and established heart disease. It is not approved for weight loss — but widespread off-label prescribing for that purpose is well established.
Wegovy is approved for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition, and for reducing cardiovascular risk in adults with obesity and established cardiovascular disease.
Why the Higher Dose Matters
The difference between 2 mg and 2.4 mg may sound small, but the STEP clinical trials showed the 2.4 mg dose produces meaningfully greater weight loss than lower doses. This is why Novo Nordisk developed and sought separate approval for Wegovy rather than simply recommending higher-dose Ozempic for weight management.
Insurance Coverage Implications
Insurance plans that cover diabetes medications (Ozempic) often do not cover obesity medications (Wegovy), and vice versa. This creates a situation where some patients can access semaglutide through an Ozempic prescription but not Wegovy, even though they are using it for weight loss. This is a frequently discussed issue in obesity medicine.
The Bottom Line for Patients
Ask your doctor specifically which formulation and which indication makes sense for you based on your health conditions and insurance situation. The medication itself is the same — the labeling, dosing, and coverage are what differ.